Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
about
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapyMET inhibitors in combination with other therapies in non-small cell lung cancerCombination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft modelA phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.Systemic therapy for advanced hepatocellular carcinoma: an update.Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumorsA comparison of epithelial-to-mesenchymal transition and re-epithelializationCytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.Recent developments in the treatment of renal cell carcinoma.A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapyGSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cellsOverexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials.Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.Targeted therapy of hepatocellular carcinoma: present and future.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Management of hepatocellular carcinoma: beyond sorafenib.MET: a promising anticancer therapeutic target.Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.Targeted therapies in the treatment of advanced hepatocellular carcinomaTargeting angiogenesis in renal cell carcinoma.Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinibNew molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions.Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats.Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein.In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugsDevelopment of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases.The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis.Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future PerspectivesMolecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.Stereoselective hydroxylation by CYP2C19 and oxidation by ADH4 in the in vitro metabolism of tivantinib.ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
P2860
Q26798420-29A5C5D9-9CDB-4F0E-9BDE-757B45C8CB8BQ26823203-C258B88F-4139-4568-BB82-6602576C50C5Q27302940-A235AC34-987E-40A0-A79B-D07161850D6AQ33162379-EA536550-B7D1-483C-823E-29CDEB81A5E4Q33414632-A504817C-3395-4D6C-97CD-631FB7A56679Q33593213-FCB29CD6-D7D6-49E5-9338-C60D6222D249Q33880542-8126D986-B575-4200-A1C1-FDF30580F43FQ35674211-C35AB9C1-406D-4B6C-BAAA-6B7D0AD512FCQ36678367-528C2CEA-8DC4-409E-8A19-5183F88AD628Q37137050-6F416B6E-8233-47A5-921C-18213E2CB387Q37300942-A39EDF4B-F108-49A1-9707-3F674FE31CDAQ37352435-267A41F6-BD48-4D0A-85E8-82510717DCE4Q37620336-F01F8BA8-2DE1-4F02-9143-FF1D84A9D656Q37663252-BD75AFE4-BDB4-49C0-8229-0352755A63EEQ37950469-BECE2BD0-B533-40C8-9EB1-3E78FD1E0870Q37968256-9231D1C4-409E-4AAB-98C4-30C8271D1ED1Q37988604-47734BCA-7184-49D4-A8DA-6DBDBCE69229Q37994505-C9CAF7EF-4FFC-48D5-A9AB-A319F3E8DC3FQ37995523-519C6A68-1EA3-4D8A-8E98-430743B6804DQ38008247-56B866EC-3EB6-4EA8-A334-3FE17EE3D9BAQ38093654-A115E614-AF04-47F5-AA54-50D580DB632EQ38114062-ED0844F0-7386-4466-92DF-64E5EFFB8053Q38132231-EC7AC554-F824-47BA-BF93-A58B0E4865E7Q38201707-B16CD1DF-41A6-4FEC-BE25-7621D160550EQ38239580-9F4B2800-D79C-4486-BF87-075388ACAA6FQ38261315-831C99FA-7BD4-4EBA-A5C6-DAFE93182B1FQ38282800-02B371D6-3F3E-4527-BADB-4B618BAFBFEDQ38596987-09732B4F-0993-428E-9E40-91494FFE43A8Q38956071-F0699C11-18CA-451A-999D-F42FA1173FFBQ38986669-D78F4C6C-75BF-4987-B469-10AC739C4096Q39216584-E78379EF-4B7B-45CF-A6D8-08661AE7A532Q39405780-C53CC418-AA43-4BB4-A3DD-1BB91789F8E0Q39604398-880D89D7-38DC-4A29-9EC4-4DC8F8013CD7Q41587809-19ADABDA-AC9C-4C21-8A80-A05281B8217EQ41706847-1E7C5C4C-3615-4FF0-8CAA-43B0D476D797Q50422614-B4CBCCF8-555E-4F26-8A3D-152C6367EE4EQ53632264-C9D8B94D-34F0-41C6-9C27-C36FC80E61BEQ55428315-4BC8F222-2950-4DDC-B412-47F11D09001B
P2860
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Early clinical development of ...... treatment of advanced cancers.
@ast
Early clinical development of ...... treatment of advanced cancers.
@en
type
label
Early clinical development of ...... treatment of advanced cancers.
@ast
Early clinical development of ...... treatment of advanced cancers.
@en
prefLabel
Early clinical development of ...... treatment of advanced cancers.
@ast
Early clinical development of ...... treatment of advanced cancers.
@en
P2860
P1433
P1476
Early clinical development of ...... treatment of advanced cancers
@en
P2093
Alex A Adjei
Edward Garmey
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0380
P577
2011-05-31T00:00:00Z